CN
Product Service Detection COLOTECT® Non-invasive DNA Methylation Colorectal Cancer Auxiliary Diagnosis Test
COLOTECT®- Non-invasive DNA Methylation Colorectal Cancer Auxiliary Diagnosis Test
The test assesses the subject's risk of developing colorectal cancer and precancerous lesions by detecting the methylation level in the DNA of intestinal exfoliated cells in the stool. It provides a more convenient, fast and accurate approach to aid the early detection of gastrointestinal diseases.
Product features
Colorectal cancer, the "invisible killer" of the cities
Usually asymptomatic in early stages and often diagnosed in intermediate to late stages

    Colorectal cancer was the third most common cancer in 2020, with the incidence showing that people are getting the disease at a younger age

    Third highest

    On average, 1 person dies of bowel cancer every 2 minutes

    1 person/2 min

    There were 1.8 million new cases worldwide in 2020 1 person is diagnosed with bowel cancer every 1 minute

    High incidence

    Bowel cancer caused 860,000 global deaths in 2020, with the mortality rate rising to the second highest among malignant cancers.

    High mortality rate

These people are susceptible to colorectal cancer

(those who meet any of the above criteria)

Sensitivity and specificity of COLOTECT® Non-invasive DNA Methylation Colorectal Cancer Auxiliary Diagnosis Test
How to use COLOTECT® Non-invasive DNA Methylation Colorectal Cancer Auxiliary Diagnosis Test

Customer Service:

+1 866 301 0097

Service Time:7*24

Language:English

E-mail: info@bgi.com

Copyright © BGI 2022. All Rights Reserved. Guangdong ICP Registration No. 16021117